Reta — Compound Overview
A researcher-focused overview of Reta: its chemistry as an engineered incretin-receptor peptide, its investigational status, and how each batch is documented.
Last updated: 2026-08-21 · By: Index Peptides technical team
Key facts about Reta
| Compound | Reta |
|---|---|
| CAS number | 2381089-83-2 |
| Molecular formula | C221H342N46O68 |
| Molecular weight | 4731.3 g/mol |
| Sequence | 39-residue modified peptide |
| Listed formats | 10mg per vial, 40mg per vial |
| Intended use | In-vitro laboratory research only |
What is Reta?
Reta is a synthetic 39-residue modified peptide engineered to act as an agonist at three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. It is built on a GIP-like backbone with non-natural amino-acid substitutions and a C20 fatty-diacid moiety attached via a linker — a lipidation strategy used to extend peptide half-life.
Chemistry and structure
Reta carries CAS registry number 2381089-83-2, molecular formula C221H342N46O68 and a molecular weight of approximately 4731.3 g/mol, making it one of the largest peptides in this catalogue. Its size and lipidation make manufacturing and analytical characterisation more demanding, which is reflected in batch-level documentation.
Regulatory status — read carefully
Reta is an investigational compound in pharmaceutical clinical development. It is NOT an approved medicine anywhere in the world, and no compounded, 'generic' or research-chemical version of it is legal to use in humans. Index Peptides supplies Reta strictly for in-vitro laboratory research, with payment and listing reviews reflecting its higher-risk status. Support cannot discuss human use of any kind.
Reta in the research literature
Reta appears in the incretin-pharmacology literature as a multi-receptor agonist tool compound, alongside published clinical-trial reports concerning the pharmaceutical development programme. Those trials concern the sponsor's controlled pharmaceutical product — they do not validate research-grade material for any use beyond the laboratory.
Form, handling and storage
Supplied as a lyophilised powder in a sealed vial. Store at -20°C, desiccated and protected from light, per the batch record. Lipidated peptides can show different solubility behaviour from unmodified peptides; reconstitution conditions are part of the experimental design and are not advised by Index Peptides.
Batch documentation at Index Peptides
Review the published certificate for the exact lot, including the laboratory, report date and analytical results actually reported. HPLC purity alone does not confirm LC-MS identity. Contact us before ordering if a required result is not published.
Frequently asked questions
Is Reta an approved weight-loss drug?
No. Reta is an investigational compound in clinical development and is not approved anywhere. The material here is for in-vitro laboratory research only — not for human use, and support cannot discuss human use.
Why is identity testing especially important for Reta?
At ~4.7 kDa with non-natural residues and a fatty-diacid modification, Reta is difficult to synthesise correctly. LC-MS identity confirmation (expected vs detected mass) on the COA is the check that the vial contains the right molecule.
Why is it invoice-only rather than direct checkout?
Reta is held to stricter payment and listing review because of its higher regulatory risk profile. Orders go through the invoice flow.
How do I reconstitute Reta?
Reconstitution is a laboratory handling procedure, not a use instruction. Our documentation-led reconstitution guide covers the mechanics of dissolving lyophilised peptide powders: https://indexpeptides.uk/guides/peptide-reconstitution-guide. Handling is the responsibility of the qualified researcher.
What is the shelf life of Reta?
As supplied (lyophilised powder in a sealed vial), Reta is stored at -20C, desiccated and protected from light. Long-term stability is documented per batch on the certificate of analysis; treat the batch record as the authoritative shelf-life reference for that lot.
What is the difference between the sizes?
The difference is the nominal peptide content per vial. Reta is supplied as 10mg and 40mg vials. Every format carries the same batch documentation and purity testing.
What does the certificate of analysis show?
Review the published certificate for the exact lot, including the laboratory, report date and analytical results actually reported. HPLC purity alone does not confirm LC-MS identity. Contact us before ordering if a required result is not published.
References
Research use only. Not for human or animal consumption.